By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Alkermes plc 

852 Winter Street

Waltham  Massachusetts  02451  U.S.A.
Phone: 781-609-6000 Fax: n/a


Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes’ website at .

Key Executives:

Richard F. Pops- Chairman and Chief Executive Officer

Shane Cooke- President

Kathryn L. Biberstein- Executive Vice President, Chief Compliance Officer and Chief Administrative Officer, and Secretary Alkermes plc

Iain Brown- Senior Vice President, Finance and Chief Accounting Officer

Madeline D. Coffin- Senior Vice President, Human Resources

Elliot W. Ehrich, M.D.- Executive Vice President, Research and Development

James M. Frates- Senior Vice President, Chief Financial Officer

David J Gaffin- Senior Vice President, Chief Legal Officer

Georgianna Harris, Ph.D.- Senior Vice President, Regulatory Affairs

Craig Hopkinson, M.D.- Chief Medical Officer, and Senior Vice President of Clinical Development and Medical Affairs

Blair C. Jackson- Senior Vice President, Business Development

Michael J. Landine- Senior Vice President, Corporate Development

Mark Namchuk, Ph.D.- Senior Vice President, Research, Pharmaceutical and Nonclinical Development

Peter Norman- Vice President, Government Affairs and Policy

Declan O’Connor- Senior Vice President, Operations

Phil Shanahan, Ph.D.- Vice President, Quality Operations

Mark P. Stejbach- Senior Vice President, Chief Commercial Officer


Alkermes Corporate Headquarters
Connaught House
1 Burlington Road
Dublin 4, Ireland
+353 1 772 8000

Waltham, Massachusetts
852 Winter Street
Waltham, MA 02451
+1 781 609 6000

Athlone, Ireland
Monksland, Athlone
Co Westmeath, Ireland
+353 90 649 5000

Gainesville, Georgia
1300 Gould Drive
Gainesville, GA 30504
+1 770 531 8100

Wilmington, Ohio
265 Olinger Circle
Wilmington, OH 45177
+1 937 382 5642

Key Statistics

Ownership: Public

Web Site: Alkermes
Employees: 1,900
Symbol: ALKS

Drug Delivery

Company News
Patients Switched To Alkermes (ALKS)’ ARISTADA Showed Significant Improvement In Schizophrenia Symptoms After Inadequate Response Or Intolerance To INVEGA SUSTENNA 9/18/2017 6:25:00 AM
Alkermes (ALKS) Announces 2nd Annual Competitive Grants Program To Support Those Affected By Mental Health And Substance Use Disorders 9/6/2017 6:32:46 AM
Alkermes (ALKS) Initiates Rolling Submission Of ALKS 5461 New Drug Application For Major Depressive Disorder 8/21/2017 7:44:12 AM
Alkermes (ALKS) Reports Second Quarter 2017 Financial Results 7/27/2017 6:26:35 AM
Alkermes (ALKS) To Host Conference Call To Discuss Second Quarter 2017 Financial Results 7/21/2017 7:51:39 AM
Alkermes (ALKS) Slips As Weight Gain Concerns Sully Late-Stage Schizophrenia Data 6/30/2017 5:46:44 AM
Alkermes (ALKS) Announces Initiation Of Study 217 For ALKS 5461 For Treatment Of Major Depressive Disorder 6/12/2017 7:56:24 AM
Alkermes (ALKS) Announces Initiation Of Phase III Study Of ALKS 3831 In Young Adult Patients 6/8/2017 6:51:22 AM
Alkermes (ALKS) Release: FDA Approves Two-Month ARISTADA For Treatment Of Schizophrenia 6/6/2017 7:08:01 AM
Alkermes (ALKS) Appoints Craig Hopkinson, M.D., As Chief Medical Officer, And Senior Vice President, Clinical Development And Medical Affairs 5/30/2017 6:02:54 AM